Professor of Medicine; Director, Advanced Heart Failure and Transplant

Vanderbilt Heart and Vascular Institute

Printed as of 6/7/2025

## **Disclosures**

| Personal Commercial (16 |
|-------------------------|
|-------------------------|

| Company Name                              | Relationship Category                   | Compensation Level       | Topic Area(s)                      |
|---|---|--------------------------|------------------------------------|
| Self                                      |   |                          |                                    |
| Abbott                                    | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Alleviant                                 | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Astra Zeneca                              | Research/Research Grants<br>‡ DEFINE-HF | None (\$0)               | Heart Failure and Cardiomyopathies |
| AstraZeneca                               | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Boston Scientific                         | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Cordio                                    | Consultant Fees/Honoraria               | None (\$0)               | Heart Failure and Cardiomyopathies |
| CVRx                                      | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Edwards                                   | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Valvular Heart Disease             |
| Impulse Dynamics                          | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Merck                                     | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Merck & Co., Inc.                         | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Novartis                                  | Consultant Fees/Honoraria               | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Sensible Medical                          | Research/Research Grants                | None (\$0)               | Heart Failure and Cardiomyopathies |
| Volumetrix                                | Research/Research Grants                | None (\$0)               | Heart Failure and Cardiomyopathies |
| VWAVE                                     | Consultant Fees/Honoraria               | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
|   |   |                          |                                    |

## Additional Personal Commercial Disclosures for Education Activities (1)

| Company Name | Relationship Category     | Compensation Level | Topic Area(s)                      |
|--------------|---------------------------|--------------------|------------------------------------|
| Self         |                           |                    |                                    |
| Medtronic    | Consultant Fees/Honoraria | None (\$0)         | Heart Failure and Cardiomyopathies |

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

# Clinical Trial Enroller (1)

| Trial Name  | Trial Sponsor | Trial Funding Source |
|-------------|---------------|----------------------|
| DICTATE-AHF | Astra Zeneca  | Astra Zeneca         |

## Institutional Financial Decision-Making Role (2)

| Funding Source | Institutional Compensation Level |
|----------------|----------------------------------|
| Astra Zeneca   | None (\$0)                       |
| VoluMetrix     | None (\$0)                       |

## Expert Witness Testimony (0)

No disclosures on record

## Agreement

Certified Education Attestation | Signed on 10/16/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/16/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/16/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/16/2024

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.